Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Zhang, Danfang ^a   Sun, Baocun ^a   Zhao, Xiulan ^a   Ma, Yuemei ^a   Ji, Ru ^a   Gu, Qiang ^a   Dong, Xueyi ^a   Li, Jing ^a   Liu, Fang ^a   Jia, Xiaohua ^a   Leng, Xue ^a   Zhang, Chong ^a   Sun, Ran ^a   Chi, Jiadong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer stem cell; Sunitinib; Triple negative breast cancer; Twist1; Vasculogenic mimicry

Indexed keywords

CD133 ANTIGEN; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; GLYCOPROTEIN; INDOLE DERIVATIVE; LEUKOCYTE ANTIGEN; NUCLEAR PROTEIN; PEPTIDE; PYRROLE DERIVATIVE; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL POPULATION; CLINICAL FEATURE; COMPARATIVE STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REOXYGENATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR XENOGRAFT; AGED; ANIMAL; ANOXIA; CANCER TRANSPLANTATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTIGENS, CD; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INDOLES; MCF-7 CELLS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASTIC CELLS, CIRCULATING; NUCLEAR PROTEINS; PEPTIDES; PYRROLES; TRIPLE NEGATIVE BREAST NEOPLASMS; TWIST TRANSCRIPTION FACTOR;

EID: 84907395529     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-207     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kummel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011, 125:145-156. 10.1007/s10549-010-1228-x, 21042932.
3. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58:2825-2831.
4. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011, 125:627-636. 10.1007/s10549-010-1293-1, 3244802, 21161370.
5. Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008, 113:608-615. 10.1002/cncr.23569, 18484596.
6. Yuan ZY, Wang SS, Gao Y, Su ZY, Luo WB, Guan ZZ. [Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases]. Ai Zheng 2008, 27:561-565.
7. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009, 115:325-333. 10.1007/s10549-008-0096-0, 18563552.
8. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948. 10.1056/NEJMra1001389, 21067385.
9. Cao Y, Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci Transl Med 2010, 2:15ps13.
10. Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009, 19:338-343. 10.1016/j.semcancer.2009.05.001, 19481151.
11. Sarmiento R, D'Andrea MR, Cacciamani F, Salerno F, Gasparini G. Antiangiogenic therapies in breast cancer. Curr Opin Investig Drugs 2009, 10:1334-1345.
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
13. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143. 10.1200/JCO.2009.26.5561, 2860433, 20368558.
14. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
15. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
16. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011, 20(Suppl 3):S56-S60.
17. Hayes DF. Bevacizumab treatment for solid tumors: boon or bust?. JAMA 2011, 305:506-508. 10.1001/jama.2011.57, 21285431.
18. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131. 10.1007/s10549-010-0788-0, 2855860, 20339913.
19. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603. 10.1038/nrc2442, 2874834, 18650835.
20. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816. 10.1200/JCO.2007.14.5375, 18347007.
21. Johannsen M, Florcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grunwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009, 55:1430-1438. 10.1016/j.eururo.2008.10.021, 18950936.
22. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
23. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155:739-752. 10.1016/S0002-9440(10)65173-5, 1866899, 10487832.
24. Sun BC, Zhang SW, Zhao XL, Hao XS. [Study on vasculogenic mimicry in malignant melanoma]. Zhonghua Bing Li Xue Za Zhi 2003, 32:539-543.
25. Shirakawa K, Kobayashi H, Sobajima J, Hashimoto D, Shimizu A, Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003, 5:136-139. 10.1186/bcr585, 165001, 12793894.
26. Liu R, Yang K, Meng C, Zhang Z, Xu Y. Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol Ther 2012, 13:527-533. 10.4161/cbt.19602, 22407030.
27. Wang JY, Sun T, Zhao XL, Zhang SW, Zhang DF, Gu Q, Wang XH, Zhao N, Qie S, Sun BC. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther 2008, 7:758-766. 10.4161/cbt.7.5.5765, 18376140.
28. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 2010, 51:545-556. 10.1002/hep.23311, 19957372.
29. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007, 249:188-197. 10.1016/j.canlet.2006.08.016, 16997457.
30. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, Yao Z, Dong XY, Zhao N, Liu N. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 2013, 32:544-553. 10.1038/onc.2012.85, 22469978.
31. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nister M, Reifenberger G, Lundeberg J, Frisén J, Acker T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133:983-995. 10.1093/brain/awq042, 20375133.
32. Zhang S, Zhang D, Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007, 254:157-164. 10.1016/j.canlet.2006.12.036, 17306454.
33. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3:411-421. 10.1038/nrc1092, 12778131.
34. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010, 36(Suppl 3):S80-S86.
35. Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, Folberg R, Hendrix MJ. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 2002, 19:233-246. 10.1023/A:1015591624171, 12067204.
36. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor RE, Hendrix MJ. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002, 44:17-27. 10.1016/S1040-8428(01)00199-8, 12398997.
37. Yao X, Ping Y, Liu Y, Chen K, Yoshimura T, Liu M, Gong W, Chen C, Niu Q, Guo D, Zhang X, Wang JM, Bian X. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One 2013, 8:e57188. 10.1371/journal.pone.0057188, 3594239, 23536763.
38. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
39. Sun T, Sun BC, Zhao XL, Zhao N, Dong XY, Che N, Yao Z, Ma YM, Gu Q, Zong WK, Liu ZY. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 2011, 54:1690-1706. 10.1002/hep.24543, 21748764.
40. Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320. 10.1056/NEJMoa1111097, 3401076, 22276821.
41. Ratner M. Fearful of Avastin's fate, Genentech asks for unusual hearing. Nat Med 2011, 17:233. 10.1038/nm0311-233, 21383702.
42. Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008, 14:7050-7059. 10.1158/1078-0432.CCR-08-0520, 18981002.
43. Sun B, Zhang S, Zhang D, Gu Y, Zhang W, Zhao X. The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model. J Cancer Res Clin Oncol 2007, 133:979-985. 10.1007/s00432-007-0245-6, 17574475.
44. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, Hendrix MJ. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 2012, 181:1115-1125. 10.1016/j.ajpath.2012.07.013, 22944600.
45. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012, 109:2784-2789. 10.1073/pnas.1018866109, 3286974, 22308314.
46. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28:3949-3959. 10.1038/onc.2009.252, 19718046.
47. Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M. Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal 2010, 12:1383-1430. 10.1089/ars.2009.2737, 19903090.
48. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK, Wu KJ. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010, 12:982-992. 10.1038/ncb2099, 20818389.
49. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
50. Borgna S, Armellin M, di Gennaro A, Maestro R, Santarosa M. Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. Cell Cycle 2012, 11:4242-4251. 10.4161/cc.22543, 3524219, 23095640.